Kiedy, dlaczego i jak rozpocząć leczenie farmakologiczne choroby Parkinsona

10.08.2021
Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how
Rob M.A. de Bie1, Carl E. Clarke2,3, Alberto J. Espay4, Susan H. Fox5, Anthony E. Lang5
1Amsterdam University Medical Centers, University of Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam, Holandia; 2Department of Neurology, City Hospital, Sandwell and West Birmingham NHS Trust, Birmingham, Wielka Brytania;3Institute for Applied Health Research, University of Birmingham, Birmingham, Wielka Brytania; 4UC Gardner Neuroscience Institute and James J and Joan A Gardner Family Center for Parkinson’s Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USA; 5Edmond J. Safra Program in Parkinson’s Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Division of Neurology, University of Toronto, Toronto, ON, Kanada
Lancet Neurol. 2020; 19: 784–794; 19: 452–461